0
Abstract: Slide Presentations |

AMBRISENTAN THERAPY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: 2-YEAR OUTCOME FREE TO VIEW

Ronald J. Oudiz, MD*
Author and Funding Information

LA Biomed Research Inst at Harbor-UCLA, on behalf of the ARIES Study Group, Torrance, CA


Chest


Chest. 2008;134(4_MeetingAbstracts):s40001. doi:10.1378/chest.134.4_MeetingAbstracts.s40001
Text Size: A A A
Published online

Abstract

PURPOSE:Ambrisentan is an ETA-selective endothelin receptor antagonist (ERA) that is approved for the treatment of pulmonary arterial hypertension (PAH) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening. Ambrisentan has been shown to improve 6-minute walk distance (6MWD) in two Phase 3, 12-week, placebo-controlled studies (ARIES-1 and ARIES-2). ARIES-E is an ongoing, long term extension study of ARIES-1 and ARIES-2. Two-year, long-term data from the ARIES studies are presented.

METHODS:This is an integrated analysis of 383 patients who received at least 1 dose of ambrisentan (2.5, 5, or 10 mg qd) in ARIES-1, ARIES-2, or ARIES-E. Patients who received placebo in the previous studies were randomized to ambrisentan in ARIES-E. The first 24 weeks of dosing in ARIES-E was a blinded, fixed-dose period. After 24 weeks, blinded dose adjustment was permitted. Baseline was defined as the time of randomization to ambrisentan.

RESULTS:Baseline subject characteristics were as follows: 63% idiopathic PAH, 37% associated PAH. Nearly all subjects were WHO class II (43%) or WHO class III (47%). Baseline 6MWD was 347 ± 85.4 meters. Two-year data from the ARIES studies will be available in July, 2008. Assessments of exercise tolerance, PAH symptoms, survival, and safety data will be presented.

CONCLUSION:Data from this analysis will provide the most comprehensive examination of the long-term safety and efficacy of ambrisentan for the treatment of PAH.

CLINICAL IMPLICATIONS:These data may support the long-term use of ETA-selective ERAs in the treatment of PAH.

DISCLOSURE:Ronald Oudiz, Grant monies (from industry related sources) Gilead Sciences; No Product/Research Disclosure Information

Tuesday, October 28, 2008

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543